Redeye makes rather small, but positive, changes to our financial forecasts on the back of strong Q2...
Redeye states that Gapwaves delivered a solid report with beats across key metrics.
Soft Q2, but heading in the right direction We forecast Q2 sales of EUR 27.
Redeye comments on the outcome of AlzeCure’s rights issue, which was significantly oversubscribed at...
India returns to growth and margins expand Medicover delivered another strong quarter, beating adj.
Redeye updates its estimates and valuation following Eniro's Q2 2025 report and a change of lead ana...
Stronger order intake, but lower sales Cavotec reported order intake of EUR 44m (+7% vs.
Redeye provides an update on NextCell following the company’s Q3 report, which came in largely in li...
Net sales and clean EBIT were below market consensus (LSEG) in Q2.
Redeye is happy to see OXE Marine beating our forecasts across the board.
Redeye comments on Polygiene Group´s Q2 2025. Polygiene Group delivered negative growth of -12% y/y.
Q2 results Medicover reported an adj. EBITDA beat in Q2 (+7%/+7% vs.
Physitrack’s Q2 2025 results came in broadly in line with our expectations.
Mentice is in the process of making the business sharper, more focused, and more efficient.
Prisma redovisade en stark Q2 med 15,5 % högre intäkter och ett förvaltningsresultat på 48 Mkr (11).
VNV Globals investeringsportfölj steg över 5% sekventiellt mätt i usd, drivet främst av uppvärdering...
Redeye returns with a more in-depth take on the Q2 report.
Redeye provides its initial take on MedCap’s Q2 2025 report, which roughly matched our top-line proj...
Q2 yet another miss As feared, Invisio faced tough comps in Q2 and missed expectations across most k...
Incap downgraded its full year outlook on 22 July 2025.
